Lumosa Therapeutics Co., Ltd.
Taipei Exchange 6535.TWO
Lumosa Therapeutics Co., Ltd. Receivables for the year ending December 31, 2023: USD 390.99 K
Lumosa Therapeutics Co., Ltd. Receivables is USD 390.99 K for the year ending December 31, 2023, a -14.38% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.
-
Lumosa Therapeutics Co., Ltd. Receivables for the year ending December 31, 2022 was USD 456.63 K, a 30.60% change year over year.
-
Lumosa Therapeutics Co., Ltd. Receivables for the year ending December 31, 2021 was USD 349.63 K, a -28.93% change year over year.
-
Lumosa Therapeutics Co., Ltd. Receivables for the year ending December 31, 2020 was USD 491.97 K, a -94.91% change year over year.
-
Lumosa Therapeutics Co., Ltd. Receivables for the year ending December 31, 2019 was USD 9.66 M.
Key data
| Date | Receivables | Inventory | Goodwill | Total Assets |
|---|
Market news
Loading...
Taipei Exchange: 6535.TWO
| CEO | Li Fang Pan |
| IPO Date | July 16, 2015 |
| Location | |
| Headquarters | No. 3-2, Park Street |
| Employees | 47 |
| Sector | Health Care |
| Industries | |
Description
Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan. The company offers LT - 1001, an analgesic injection that has completed Phase III clinical trials for severe pain relief after surgery. It is also developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase Ib clinical trial for uremic pruritus; and LT2003, which is in pre-clinical stage for the treatment of oncology. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is based in Taipei, Taiwan.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email